Restoring Function & Enhancing Lives

Histogen is a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body’s natural process to repair and maintain healthy biological function. Histogen’s innovative technology platform utilizes cell conditioned media and extracellular matrix materials produced by hypoxia-induced multipotent cells. Histogen’s proprietary, reproducible manufacturing process provides targeted solutions across a broad range of therapeutic indications including hair growth, dermal rejuvenation, joint cartilage regeneration and spinal disk repair.

clinical programs

Histogen is advancing three clinical programs in therapeutic indications with large commercial market opportunities:

HAIR GROWTH

Hair Growth

A minimally-invasive treatment that is intended to grow new hair, not simply preserve existing hair.

SKIN CARE

Dermal Fillers

Human-derived collagen and extracellular matrix dermal fillers delivering potentially longer-lasting effects with fewer side effects for the treatment of facial folds and wrinkles.

MATRIX REGENERATION

Joint Cartilage Repair

Histogen’s extracellular matrix for articular cartilage defects regenerates hyaline cartilage for the treatment of knee osteoarthritis with a novel malleable scaffold produced by the body’s own stem cells.

Latest News

July 29, 2021
Histogen to Present at the Canaccord Genuity 41st Annual Growth Conference

SAN DIEGO, July 29, 2021 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body’s natural process to repair and maintain healthy biological function, today announced that

July 28, 2021
Histogen to Report Second Quarter 2021 Financial Results on August 11, 2021

SAN DIEGO, July 28, 2021 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body’s natural process to repair and maintain healthy biological function, today announced that

June 30, 2021
Histogen Announces Initiation of HST 003 Phase 1/2 Trial for Knee Cartilage Regeneration

SAN DIEGO, June 30, 2021 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), today announced the initiation of its Phase 1/2 clinical trial of HST 003 to evaluate the safety and efficacy of human extracellular matrix (hECM:HST 003) implanted within microfracture interstices and the cartilage defect